| Metric | H1 FY27 | H1 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 48.9 | 0.0 | 14.4 |
| Total income | 49.0 | 0.0 | 14.4 |
| Profit before exceptional items & tax | 6.8 | 0.0 | 2.4 |
| Profit before tax | 6.8 | 0.0 | 2.4 |
| Net profit | 5.1 | 0.0 | 1.7 |
| Operating margin | 13.9% | 0.0% | 16.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +200.00% |
|---|---|
| Revenue, year on year | +239.60% |
BSE results filing, BSE: 544529. Figures extracted from the filing.
Aptus Pharma Ltd: key numbers
- Share price
- ₹462.70
- Market cap
- ₹793.5 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 171.8×Sector 46.1×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months
Aptus Pharma Annual Report
Aptus Pharma has filed its Annual Report for FY 2025-26 with the exchange. The report includes the notice for the upcoming 16th Annual General Meeting.
Aptus Pharma Annual General Meeting
Aptus Pharma Limited issued a notice for its 16th AGM on September 14, 2026, which includes a proposal for a preferential allotment of equity shares.
- Value
- ₹44.88 Cr